Replies to post #111899 on Biotech Values

[mcbio]

ACHN’s presentation at APASL is merely PK data, according to the PR in #msg-57411658, so I think the Seeking Alpha article in #msg-58253083 is just blowing smoke.

Isn't there still the point, though, as to why ACHN would present essentially meaningless data at a conference if they were seeing some sort of problem in the ongoing Phase 2a trials of the drug? I.e., it's not like presenting this data at the conference is likely to move the stock so they're likely not presenting in hopes of bumping the share price up and doing an offering. So, what other incentive would there be to present if there was some issue with the drug that they're seeing in the ongoing Phase 2a?